

Supporting Information

Organocatalytic One Pot Asymmetric Synthesis of 4*H*,5*H*-Pyrano[2,3-*c*]pyrazoles

Dieter Enders,^{*,†} André Grossmann,[†] Bianca Gieraths,[†] Muharrem Düzdemir,[†] and Carina Merkens[‡]

Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany, and Institute of Inorganic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany

enders@rwth-aachen.de

Contents

1. General Methods	2
2. Materials	2
3. General Procedure for the Asymmetric Michael/Wittig/oxa-Michael One Pot Reaction..	3
4. Solvent Screening of the Asymmetric Michael/Acetalization Cascade Reaction.....	3
5. Optimization of the Ring opening/Wittig/oxa-Michael Cascade	4
6. Epimerization/Decomposition Experiment of Compound 9a	4
7. Analytical data.....	5
8. NMR Spectra.....	15
9. NOESY of Compounds 13e and 13f	30
10. HPLC Chromatograms.....	32

[†] Institute of Organic Chemistry

[‡] Institute of Inorganic Chemistry

1. General Methods

- **Preparative column chromatography:** Merck silica gel 60, particle size 0.040-0.063 mm (230-240 mesh, flash).
- **Analytical TLC:** SIL G-25 UV254 from MACHEREY&NAGEL. Visualization of the developed TLC plates was performed with ultraviolet irradiation (254 nm) or by staining with basic potassium permanganate solution.
- **Optical rotation** values were measured on a Perkin-Elmer 241 polarimeter.
- **Microanalyses** were performed with a Vario EL element analyzer.
- **Mass spectra** were acquired on a Finnigan SSQ7000 (EI/CI) spectrometer and high resolution mass spectra on a Finnigan MAT 95 (EI/CI) or on a ThermoFisher Scientific LTQOrbitrap XL (ESI). All signals over 10% relative intensity are listed.
- **IR spectra** were taken on a Perkin-Elmer FT-IR Spectrum 100 using a Diamant/KRS5 ATR.
- **¹H-, ¹³C- and ¹⁹F-NMR** spectra were recorded at ambient temperature on Varian Mercury 300, VNMRs 600 and Inova 400 instruments with tetramethylsilane as an internal standard.
- **Analytical HPLC** was performed on a Hewlett-Packard 1100 Series instrument using chiral stationary phases (Daicel AD, Daicel IA, Daicel OD).

2. Materials

- Trifluoromethylpyrazolones **7a** and **7b** were purchased from Fluorochem and ABCR and were used as received.
 - Catalysts **10-11** were purchased from Sigma Aldrich and were used as received.
 - Aldehydes **6a-f** were purchased from Sigma Aldrich, distilled and stored in the fridge previous to use.
 - Aldehydes **6g**,¹ **6h**,² **6i**³ were synthesized according to the literature procedures.
 - Organocatalysts **8a-c**⁴ and **8d**⁵ were prepared according to the literature procedure.
 - The **racemic products** were prepared using morpholine instead of **8b** as the catalyst and chloroform as sole solvent.⁶
 - CHCl₃ (spectroscopy grade) was purchased from a commercial source and used as received.
- All other solvents were of technical grade and dried using common purification techniques.

(1) Bulger, P. G.; Moloney, M. G.; Trippier, P. C. *Org. Biomol. Chem.* **2003**, *1*, 3726-3737.

(2) Boone, M. A.; McDonald, F. E.; Lichter, J.; Lutz, S.; Cao, R.; Hardecastle, K. I. *Org. Lett.* **2009**, *11*, 851.


(3) Belardi, J. K.; Curtis, L. A.; Clareen, S. S.; Shimp, H. L.; Leimkuhler, C. E.; Simonowicz, N. L.; Casillas, E. *Synth. Commun.* **2005**, *35*, 1633-1640.

(4) Marigo, M.; Wabnitz, T. C.; Fielenbach, D.; Jørgensen, K. A. *Angew. Chem.* **2005**, *117*, 804-807; *Angew. Chem. Int. Ed. Engl.* **2005**, *44*, 794.

(5) Sparr, C. Tanzer, E.-M.; Bachmann, J.; Gilmour, R. *Synthesis* **2010**, 1394-1397.

(6) Morpholine led to complex mixtures of products, when a toluene/methanol mixture was used as solvent.

3. General Procedure for the Asymmetric Michael/Wittig/oxa-Michael One Pot Reaction



A solution of trifluoromethyl pyrazolone **7** (1.0 mmol, 1.0 equiv.) and catalyst **8b** (0.20 mmol, 0.2 equiv.) in toluene/methanol 10:1 (3 mL) was cooled to -78 °C. Subsequently, a solution of the aldehyde **6** was added dropwise. After the mixture was stirred for 24 h chloroform (4 mL) was added and the temperature was raised to -20 °C. Finally, phosphorus ylide **12** was added in one portion and the reaction was continued stirring for 24 h while the reaction was allowed to reach room temperature. The crude product was transferred on a small amount of silica and then directly purified by column chromatography gaining the products **13** as an inseparable mixture of diastereomers.

4. Solvent Screening of the Asymmetric Michael/Acetalization Cascade Reaction^a

entry	cat. (mol%)	solvent	yield ^b (%)	er ^c
1	8b (2.5)	CHCl ₃	76	83:17
2	8b (2.5)	CH ₂ Cl ₂	82	83:17
3	8b (2.5)	Toluene	94	83:17
4	8b (2.5)	THF	37	76:24
5	8b (2.5)	CH ₃ CN	32	71:29
6	8b (2.5)	EtOAc	41	71:29
7	8b (2.5)	MeOH	34	66:34
8	8b (2.5)	DMSO	37	70:30
9	8b (2.5)	1,4-Dioxane	44	76:24

^a Reaction conditions: **6a** (1.0 mmol), **7a** (1.0 mmol), solvent (4.0 mL).

^b Yields of **9a** were determined via ¹H NMR spectroscopy using 4,4'-di-tert-butylbiphenyl (DTBP) as internal standard; sum of isomers.


^c Enantiomeric ratios were determined by HPLC analysis on a chiral stationary phase after converting **9a** to **13k**.

5. Optimization of the Ring opening/Wittig/oxa-Michael Cascade^a

entry	solvent	T / °C	t / h	yield ^b (%)	dr ^c
1	CDCl ₃	rt	24	76	73:27
2	EtOH	rt	24	75	71:29
3	Acetone	rt	24	78	77:23
4	CH ₂ Cl ₂	rt	24	85	76:24
5	DMSO	rt	24	62	74:26
6	THF	rt	24	65	78:22
7	Toluene	rt	24	86	71:29
8	Toluene	reflux	2	n.d.	70:30
9	Toluene/MeOH10:1	rt	9	67	72:28

^a Reaction conditions: **9a** (1.0 mmol), **12k** (1.0 mmol), solvent (8.0 mL). ^b Yields of isolated **13k**; sum of diastereomers. ^c Diastereomeric ratio was determined by HPLC analysis or ¹H NMR spectroscopy. n.d. = not determined.

6. Epimerization/Decomposition Experiment of Compound **9a**




A solution of acetal **9a** (0.25 mmol) in toluene/methanol 10:1 (1 mL) was treated with **(R)-8b** (0.25 mmol) or morpholine (0.25 mmol) and stirred at ambient temperature for 24 h. Subsequently, chloroform (1 mL) and the Wittig reagent **12k** (0.25 mmol) were added while the reaction mixture was stirred for additional 24 h. Finally, compounds **13k** was directly purified by column chromatography (Et₂O/n-pentane 1:1) yielding the corresponding product as a colorless oil.

entry	catalyst	yield ^a (%)	dr ^b	er ^b (<i>trans</i>)	er ^b (<i>cis</i>)
1	none	76	71:29	89:11	88:12
2	(R)-8b	25	72:28	75:25	71:29
3	morpholine	38	71:29	89:11	88:12

^a Yields of isolated **13k**; sum of diastereomers. ^b The diastereomeric and enantiomeric ratio was determined by HPLC analysis on a chiral stationary phase.


7. Analytical data



13a

2-((4*R*,6*S*)-1,4-Dimethyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)-1-(3-methoxyphenyl)ethanone (13a) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13a** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7μm 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), *t_R* = 18.58 min (*trans*), *t_R* ~ 19.00 min (*cis*).⁷ The *ee* (*trans* 92%, *cis* 92%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 0.7 mL/min), *t_R* = 15.93 min (*trans*, major), 21.49 min (*trans*, minor), *t_R* = 23.53 min (*cis*, major), 25.77 min (*cis*, minor). *R_f* = 0.21 (**13a**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{25} = +19.2$ (*c* = 1.0, CHCl₃), $[\alpha]_{365}^{24} = +62.8$ (*c* = 1.0, CHCl₃); IR (ATR): 3219, 2953, 1685, 1583, 1489, 1433, 1354, 1259, 1165, 1117, 1030, 892, 851, 776, 725 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.30 (d, *J* = 6.9 Hz, 3H), 1.85 (dt, *J* = 14.4 Hz, 2.5 Hz, 1H), 1.90 (ddd, *J* = 15.9 Hz, 10.4 Hz, 5.5 Hz, 1H), 3.00 – 3.07 (m, 1H), 3.20 (dd, *J* = 16.8 Hz, 5.9 Hz, 1H), 3.59 (s, 3H), 3.60 (dd, *J* = 16.8 Hz, 6.4 Hz, 1H), 3.87 (s, 3H), 4.93 – 4.99 (m, 1H), 7.16 (ddd, *J* = 8.4 Hz, 2.5 Hz, 1.0 Hz, 1H), 7.41 (t, *J* = 8.2 Hz, 1H), 7.52 (dd, *J* = 2.5 Hz, 1.5 Hz, 1H), 7.56 (dt, *J* = 7.9 Hz, 1.0 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 22.2, 23.0, 33.8, 35.1, 43.3, 55.4, 72.7, 100.4, 112.4, 119.9, 120.7, 121.6 (q, *J* = 269.6 Hz, CF₃) 129.7, 136.9 (q, *J* = 36.9 Hz), 138.0, 150.0, 159.9, 196.2 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.9 ppm; MS (EI, 75 eV): *m/z* 368 (M⁺, 26%), 135 (100), 107 (14); HRMS (ESI): *m/z* calcd for C₁₈H₂₀F₃N₂O₃⁺: 369.1421 [M+H⁺]; found: 369.1409.




13b

1-(3-Methoxyphenyl)-2-((4*R*,6*S*)-4-methyl-1-phenyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)ethanone (13b) was purified by flash chromatography (*n*-pentane/Et₂O 2:1) yielding an inseparable mixture of diastereomers of **13b** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7μm 250x25 mm,

(7) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.

n-pentane/diethylether 6:4, 18 mL/min), t_R = 12.14 min (*trans*), t_R ~ 12.70 min (*cis*).⁷ The *ee* (*trans* 87%, *cis* 85%) was determined by HPLC on a chiral stationary phase (Daicel IA, *n*-heptane/*i*PrOH 9:1, 1.0 mL/min), t_R = 6.33 min (*trans*, major), 7.01 min (*cis*, minor), t_R = 8.11 min (*trans*, minor), 9.59 min (*cis*, major). R_f = 0.48 (**13b**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{26}$ = +1.8 (c = 1.0, CHCl₃), $[\alpha]_{365}^{26}$ = -31.9 (c = 1.0, CHCl₃); IR (ATR): 3072, 2966, 2875, 1951, 1875, 1686, 1593, 1517, 1481, 1397, 1350, 1261, 1131, 1023, 874, 840, 761, 690, 634, 565, 505 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.36 (d, J = 6.9 Hz, 3H), 1.90 (dt, J = 13.4 Hz, 2.5 Hz, 1H), 1.97 (ddd, J = 15.9 Hz, 10.4 Hz, 5.5 Hz, 1H), 3.05 – 3.15 (m, 1H), 3.22 (dd, J = 16.4 Hz, 6.0 Hz, 1H), 3.61 (dd, J = 16.8 Hz, 6.9 Hz, 1H), 3.83 (s, 3H), 4.97 - 5.05 (m, 1H), 7.14 (dd, J = 8.4 Hz, 1.9 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 7.31 (t, J = 8.4 Hz, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.50 (dd, J = 2.5 Hz, 1.5 Hz, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.65 (dd, J = 8.9 Hz, 1.5 Hz, 2H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 22.3, 23.1, 34.8, 43.3, 55.4, 73.5, 101.7, 112.4, 120.0, 120.8, 121.0, 121.5 (q, J = 269.6 Hz, CF₃), 126.7, 128.9, 129.7, 137.7, 138.0, 138.7 (q, J = 36.9 Hz), 149.9, 159.9, 196.4 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 62.1 ppm; MS (CI, 100 eV): m/z 432 (M+H⁺, 15%), 255 (17), 205 (15), 204 (100), 177 (84); HRMS (ESI): m/z calcd for C₂₃H₂₂F₃N₂O₃⁺: 431.1577 [M +H⁺]; found: 431.1577.




2-((4*R*,6*S*)-4-Ethyl-1-methyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)-1-(3-methoxyphenyl)ethanone (13c) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding inseparable mixture of diastereomers of **13c** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7μm 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 17.79 min (*trans*), t_R ~ 17.00 min (*cis*).⁸ The *ee* (*trans* 94%, *cis* 95%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/EtOH 97:3, 0.3 mL/min), t_R = 34.91 min (*trans*, major), 49.73 min (*cis*, minor), t_R = 51.95 min (*trans*, minor), 56.84 min (*cis*, major). R_f = 0.21 (**13c**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{25}$ = +9.8 (c = 1.0, CHCl₃), $[\alpha]_{365}^{25}$ = +43.9 (c = 1.0, CHCl₃); IR (ATR): 2956, 1685, 1585, 1548, 1491, 1429, 1354, 1256, 1161, 1116, 1040, 991, 887, 785, 730, 684 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.01 (t, J = 7.4 Hz, 3H), 1.45 - 1.55 (m, 1H), 1.74 (ddd, J = 16.4 Hz, 10.9 Hz, 5.5 Hz, 1H), 1.80 – 1.86 (m, 1H), 2.09 (dt, J = 14.4 Hz, 2.0 Hz, 1H), 2.75 – 2.80 (m, 1H), 3.22 (dd, J = 16.8 Hz, 6.0 Hz, 1H), 3.59 (s, 3H), 3.60 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 3.88 (s, 3H), 4.89 - 4.95 (m, 1H), 7.16 (dd, J = 7.9 Hz, 2.5 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.52 (t, J = 2.0 Hz, 1H), 7.57 (d, J = 7.4 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 11.6, 28.7, 30.0, 30.9, 33.8, 43.5, 55.5, 72.9, 99.8, 112.4, 120.0, 120.7, 121.8 (q, J = 268.3 Hz, CF₃), 129.7, 137.1 (q, J = 38.2 Hz), 138.1, 150.1, 160.0, 196.3 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.7

(8) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.


ppm; MS (EI, 75 eV): m/z 383 (M^+ , 56%), 203 (41), 135 (100), 107 (14); HRMS (ESI): m/z calcd for $C_{19}H_{22}F_3N_2O_3^+$: 383.1577 [$M+H^+$]; found: 383.1577.



13d

1-(3-Methoxyphenyl)-2-((4R,6S)-1-methyl-4-propyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-c]pyrazol-6-yl)ethanone (13d) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13d** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 17.16 min (*trans*), t_R ~ 17.00 min (*cis*).⁹ The *ee* (*trans* 95%, *cis* >99%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 0.7 mL/min), t_R = 13.14 min (*trans*, major), 16.74 min (*trans*, minor), t_R = 18.38 min (*cis*, major), 30.88 min (*cis*, minor). R_f = 0.21 (**13d**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{24}$ = +8.5 (c = 1.0, CHCl₃), $[\alpha]_{365}^{24}$ = +37.9 (c = 1.0, CHCl₃); IR (ATR): 2930, 2869, 2322, 2110, 1740, 1685, 1585, 1546, 1492, 1429, 1396, 1354, 1257, 1162, 1118, 1037, 991, 930, 854, 783, 730, 683 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 0.96 (t, J = 6.9 Hz, 3H), 1.33 – 1.40 (m, 1H), 1.46 – 1.55 (m, 2H), 1.65 – 1.80 (m, 2H), 2.06 (dt, J = 14.4 Hz, 2.0 Hz, 1H), 2.85 – 2.90 (m, 1H), 3.21 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 3.59 (s, 3H), 3.61 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 3.88 (s, 3H), 4.89 – 4.95 (m, 1H), 7.16 (dd, J = 7.4 Hz, 1.5 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.52 (t, J = 2.0 Hz, 1H), 7.57 (dt, J = 8.4 Hz, 1.0 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 13.9, 20.1, 28.0, 31.4, 33.8, 38.0, 43.5, 55.5, 72.8, 99.9, 112.4, 120.0, 120.7, 121.7 (q, J = 269.6 Hz, CF₃), 129.7, 136.9 (q, J = 36.9 Hz), 138.1, 150.1, 160.0, 196.4 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.6 ppm; MS (CI, 100 eV): m/z 397 ($M+H^+$, 100%), 396 (11), 377 (55), 61 (16); elemental analysis calcd (%) for C₂₀H₂₃F₃N₂O₃: C 60.60, H 5.85, N 7.07; found: C 60.64, H 6.18, N 7.33.



13e

2-((4R,6S)-4-Isopropyl-1-methyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-c]pyrazol-6-yl)-1-(3-methoxyphenyl)ethanone (13e) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13e** as a colorless oil. For analytical purposes samples of the *trans*-


(9) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.

diastereomer and *cis*-diastereomers were obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 17.10 min (*trans*), t_R = 16.30 min (*cis*). The *ee* (*trans* 93%, *cis* 95%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 1.0 mL/min), t_R = 7.18 min (*trans*, major), 10.09 min (*cis*, major), t_R = 10.48 min (*trans*, minor), 14.00 min (*cis*, minor). R_f = 0.17 (**13e**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{24}$ = +8.4 (c = 1.0, CHCl₃), $[\alpha]_{365}^{24}$ = +45.9 (c = 1.0, CHCl₃); IR (ATR): 2957, 2325, 2099, 1684, 1582, 1483, 1430, 1358, 1259, 1119, 1035, 874, 784, 734, 686, 540 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 0.94 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 1.65 (ddd, J = 16.4 Hz, 10.4 Hz, 6.0 Hz, 1H), 2.00 – 2.08 (m, 1H), 2.18 (dt, J = 14.4 Hz, 2.5 Hz, 1H), 2.73 – 2.77 (m, 1H), 3.19 (dd, J = 16.8 Hz, 6.9 Hz, 1H), 3.56 (dd, J = 16.8 Hz, 6.0 Hz, 1H), 3.59 (s, 3H), 3.87 (s, 3H), 4.96 – 5.02 (m, 1H), 7.15 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.51 (t, J = 2.0 Hz, 1H), 7.55 (dt, J = 7.9 Hz, 1.5 Hz, 1H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 18.8, 20.7, 29.0, 31.7, 33.8, 34.3, 43.6, 55.4, 74.1, 98.2, 112.3, 120.0, 120.7, 121.7 (q, J = 268.7 Hz, CF₃), 129.7, 137.3 (q, J = 36.5 Hz), 137.9, 150.2, 159.9, 196.4 ppm; ¹⁹F NMR (282 MHz, CDCl₃): δ = 60.9 ppm; MS (CI, 100 eV): m/z 397 (M+H⁺, 100%), 377 (48).

cis-Diastereomer: $[\alpha]_D^{24}$ = -48.9 (c = 1.0, CHCl₃), $[\alpha]_{365}^{24}$ = -180.5 (c = 1.0, CHCl₃); IR (ATR): 2961, 2325, 2095, 1686, 1582, 1544, 1486, 1428, 1393, 1354, 1294, 1256, 1163, 1115, 1041, 995, 883, 763, 728, 684, 556 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 0.68 (d, J = 6.9 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H), 1.54 – 1.61 (m, 1H), 2.02 (ddd, J = 13.9 Hz, 6.4 Hz, 1.5 Hz, 1H), 2.37 – 2.45 (m, 1H), 3.04 (ddd, J = 10.4 Hz, 6.0 Hz, 3.5 Hz, 1H), 3.25 (dd, J = 16.8 Hz, 6.0 Hz, 1H), 3.59 (s, 3H), 3.61 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 3.88 (s, 3H), 4.72 – 4.78 (m, 1H), 7.16 (dd, J = 7.4 Hz, 1.9 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.52 (t, J = 1.9 Hz, 1H), 7.58 (dt, J = 7.4 Hz, 1.5 Hz, 1H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ = 15.1, 20.4, 27.7, 28.3, 33.8, 35.9, 44.0, 55.5, 76.9, 98.8, 112.4, 120.0, 120.8, 121.7 (q, J = 268.7 Hz, CF₃), 129.7, 136.8 (q, J = 37.1 Hz), 138.0, 151.5, 159.9, 196.2 ppm; ¹⁹F NMR (282 MHz, CDCl₃): δ = 61.6 ppm; MS (CI, 100 eV): m/z 397 (M+H⁺, 27%), 377 (11), 231 (27), 221 (40), 205 (10), 201 (13), 178 (12), 177 (100), 135 (36).

Elemental analysis calcd (%) for C₂₀H₂₃F₃N₂O₃: C 60.60, H 5.85, N 7.07; found: C 60.59, H 5.48, N 7.21.




13f

1-(3-Methoxyphenyl)-2-((4*R*,6*S*)-1-methyl-4-phenyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)ethanone (13f) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13f** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 65:35, 18 mL/min), t_R = 25.84 min (*trans*), t_R = 26.50 min (*cis*). The *ee* (*trans* 76%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 1.0 mL/min),

t_R = 13.34 min (*trans*, major), 17.46 min (*trans*, minor), t_R = 25.47 min (*cis*, unseparated). R_f = 0.26 (**13f**), (*n*-pentane/Et₂O 2:1);


trans-Diastereomer: $[\alpha]_D^{26}$ = +3.3 (c = 1.0, CHCl₃), $[\alpha]_{365}^{26}$ = +4.9 (c = 1.0, CHCl₃); IR (ATR): 2944, 2321, 2099, 1686, 1588, 1548, 1494, 1430, 1350, 1256, 1161, 1119, 1035, 878, 757, 697 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 2.11 (dt, J = 14.4 Hz, 2.5 Hz, 1H), 2.22 (ddd, J = 14.4 Hz, 10.9 Hz, 6.0 Hz, 1H), 3.07 (dd, J = 16.8 Hz, 4.5 Hz, 1H), 3.54 (dd, J = 16.8 Hz, 7.4 Hz, 1H), 3.64 (s, 3H), 3.83 (s, 3H), 4.26 (d, J = 3.5 Hz, 1H), 4.79 – 4.84 (m, 1H), 7.11 – 7.15 (m, 3H), 7.22 (t, J = 7.4 Hz, 1H), 7.30 (t, J = 7.4 Hz, 2H), 7.37 (t, J = 7.9 Hz, 1H), 7.45 (t, J = 2.5 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 33.9, 34.1, 36.8, 43.0, 55.4, 72.5, 96.1, 112.4, 119.9, 120.7, 121.3 (q, J = 269.6 Hz, CF₃), 126.7, 127.6, 128.4, 129.6, 137.6 (q, J = 38.2 Hz), 138.0, 143.8, 151.2, 159.9, 195.8 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 62.3 ppm; MS (CI, 100 eV): m/z 431 (M+H⁺, 100%), 412 (11), 411 (41); elemental analysis calcd (%) for C₂₃H₂₁F₃N₂O₃: C 64.18, H 4.92, N 6.51; found: C 64.22, H 5.11, N 6.38.



13g


2-((4*R*,6*S*)-4-Benzyl-1-methyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)-1-(3-methoxyphenyl)ethanone (13g**)** was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13g** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 19.21 min (*trans*), t_R = 17.55 min (*cis*). The *ee* (*trans* 93%, *cis* >99%) was determined by HPLC on a chiral stationary phase (Daicel OD, *n*-heptane/*i*PrOH 97:3, 0.7 mL/min), t_R = 25.36 min (*trans*, major), 28.29 min (*trans*, minor), t_R = 32.16 min (*cis*, minor), 53.64 min (*cis*, major). R_f = 0.21 (**13g**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{24}$ = -11.1 (c = 1.0, CHCl₃), $[\alpha]_{365}^{24}$ = -21.2 (c = 1.0, CHCl₃); IR (ATR): 3025, 2935, 2111, 1684, 1586, 1547, 1493, 1429, 1354, 1257, 1162, 1116, 1044, 1001, 941, 854, 782, 728, 694 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.57 (ddd, J = 14.4 Hz, 11.4 Hz, 6.0 Hz, 1H), 1.94 (dt, J = 14.4 Hz, 1.5 Hz, 1H), 2.63 (dd, J = 13.9 Hz, 11.4 Hz, 1H), 3.08 – 3.13 (m, 1H), 3.15 – 3.21 (m, 2H), 3.57 (dd, J = 16.8 Hz, 6.0 Hz, 1H), 3.63 (s, 3H), 3.87 (s, 3H), 4.94 – 5.00 (m, 1H), 7.15 (dd, J = 8.4 Hz, 2.5 Hz, 1H), 7.22 (t, J = 6.9 Hz, 1H), 7.25 (d, J = 6.4 Hz, 2H), 7.31 (t, J = 7.9 Hz, 2H), 7.40 (t, J = 7.9 Hz, 1H), 7.50 (t, J = 1.9 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 30.2, 30.7, 33.8, 42.0, 43.6, 55.4, 72.7, 99.2, 112.4, 119.9, 120.7, 121.8 (q, J = 269.6 Hz, CF₃), 126.3, 128.4, 129.3, 129.7, 137.0 (q, J = 38.2 Hz), 137.9, 139.4, 150.4, 159.9, 196.0 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.5 ppm; MS (CI, 100 eV): m/z 445 (M+H⁺, 100%), 425 (33), 353 (12), 135 (17), 61 (25); elemental analysis calcd (%) for C₂₄H₂₃F₃N₂O₃: C 64.86, H 5.22, N 6.30; found: C 64.84, H 5.67, N 6.21.



1-(3-Methoxyphenyl)-2-((4R,6S)-1-methyl-3-(trifluoromethyl)-4-(((triisopropylsilyl)oxy)methyl)-1,4,5,6-tetrahydropyrano[2,3-c]pyrazol-6-yl)ethanone (13h) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13h** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7μm 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), *t_R* = 14.26 min (*trans*), *t_R* ~ 14.20 min (*cis*).¹⁰ The *ee* (*trans* 97%, *cis* >99%) was determined by HPLC on a chiral stationary phase (Daicel IA, *n*-heptane/*i*PrOH 95:5, 0.5 mL/min), *t_R* = 10.53 min (*trans*, minor), 11.37 min (*trans*, major), *t_R* = 12.17 min (*cis*, major), 13.07 min (*cis*, minor). *R_f* = 0.37 (**13h**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: $[\alpha]_D^{26} = +22.7$ (*c* = 1.0, CHCl₃), $[\alpha]_{365}^{26} = +94.6$ (*c* = 1.0, CHCl₃); IR (ATR): 3222, 2941, 2868, 1688, 1584, 1549, 1461, 1361, 1259, 1173, 1113, 1013, 886, 830, 781, 727, 682 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.01 – 1.13 (m, 21H), 1.78 (ddd, *J* = 14.4 Hz, 11.9 Hz, 6.0 Hz, 1H), 2.39 (dt, *J* = 14.4 Hz, 1.9 Hz, 1H), 3.03 – 3.08 (m, 1H), 3.17 (dd, *J* = 16.4 Hz, 5.0 Hz, 1H), 3.54 – 3.60 (m, 4H), 3.62 (t, *J* = 9.9 Hz, 1H), 3.88 (s, 3H), 3.96 (dd, *J* = 9.9 Hz, 4.0 Hz, 1H), 4.99 – 5.05 (m, 1H), 7.15 (dd, *J* = 8.4 Hz, 3.0 Hz, 1H), 7.41 (t, *J* = 7.9 Hz, 1H), 7.52 (dd, *J* = 2.5 Hz, 1.5 Hz, 1H), 7.57 (dt, *J* = 7.4 Hz, 1.3 Hz, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 11.9, 17.9, 29.2, 31.6, 33.9, 43.8, 55.5, 65.4, 73.1, 95.1, 112.5, 119.9, 120.8, 121.5 (q, *J* = 269.5 Hz, CF₃), 129.7, 137.3 (q, *J* = 37.3 Hz), 138.2, 151.2, 160.0, 196.0 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.8 ppm; MS (CI, 100 eV): *m/z* 541 (M+H⁺, 52%), 498 (15), 497 (48), 368 (17), 367 (80), 346 (21), 345 (100), 135 (32); elemental analysis calcd (%) for C₂₇H₃₉F₃N₂O₄Si: C 59.98, H 7.27, N 5.18; found: C 59.82, H 7.35, N 5.57.




((4R,6S)-6-(2-(3-Methoxyphenyl)-2-oxoethyl)-1-methyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-c]pyrazol-4-yl)methyl benzoate (13i) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13i** as a colorless oil. For analytical

(10) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.

purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 28.13 min (*trans*), t_R ~ 27.90 min (*cis*).¹¹ The *ee* (*trans* 91%) was determined after the separation of the diastereomers by HPLC on a chiral stationary phase (Daicel OD, *n*-heptane/*i*PrOH 7:3, 0.7 mL/min), t_R = 10.77 min (*trans*, minor), 13.48 min (*trans*, major). R_f = 0.25 (**13i**), (*n*-pentane/Et₂O 1:1);

trans-Diastereomer: $[\alpha]_D^{26}$ = +1.0 (c = 0.50, CHCl₃), $[\alpha]_{365}^{26}$ = -2.2 (c = 0.50, CHCl₃); IR (ATR): 2947, 2325, 2229, 2189, 2157, 2113, 2077, 2049, 2005, 1963, 1717, 1687, 1585, 1549, 1493, 1432, 1260, 1164, 1112, 1026, 972, 862, 785, 712 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 1.90 (ddd, J = 14.4 Hz, 11.4 Hz, 5.5 Hz, 1H), 2.27 (dt, J = 14.9 Hz, 2.0 Hz, 1H), 3.24 (dd, J = 16.9 Hz, 5.5 Hz, 1H), 3.39 – 3.44 (m, 1H), 3.60 (dd, J = 16.8 Hz, 6.9 Hz, 1H), 3.62 (s, 3H), 3.87 (s, 3H), 3.40 (t, J = 9.9 Hz, 1H), 4.56 (dd, J = 11.4 Hz, 4.0 Hz, 1H), 5.05 – 5.10 (m, 1H), 7.15 (dd, J = 7.9 Hz, 2.5 Hz, 1H), 7.38 – 7.48 (m, 3H), 7.51 (t, J = 1.5 Hz, 1H), 7.54 – 7.59 (m, 2H), 8.06 (dd, J = 7.9 Hz, 1.5 Hz, 2H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ 28.6, 29.7, 34.0, 43.5, 55.5, 66.2, 72.9, 94.0, 112.5, 120.0, 120.8, 121.4 (q, J = 269.6 Hz, CF₃), 128.4, 129.6, 129.7, 130.0, 133.1, 137.5 (q, J = 36.9 Hz), 138.0, 151.2, 160.0, 166.3, 195.7 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.8 ppm; MS (CI, 100 eV): m/z 489 (M+H⁺, 34%), 469 (28), 368 (19), 367 (100), 366 (13), 135 (15), 123 (35), 61 (28); elemental analysis calcd (%) for C₂₅H₂₃F₃N₂O₅: C 61.47, H 4.75, N 5.74; found: C 61.21, H 4.85, N 5.41.




2-((4*R*,6*S*)-4-Benzyl-1-phenyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)-1-(4-bromophenyl)ethanone (13j**)** was purified by flash chromatography (*n*-pentane/Et₂O 2:1) yielding an inseparable mixture of diastereomers of **13j** as a colorless solid. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 11.18 min (*trans*), t_R = 12.84 min (*cis*). The *ee* (*trans* 96%, *cis* 86%) was determined by HPLC on a chiral stationary phase (Daicel IA, *n*-heptane/EtOH 97:3, 0.5 mL/min), t_R = 20.50 min (*trans*, major), 21.81 min (*trans*, minor), t_R = 24.51 min (*cis*, major), 25.83 min (*cis*, minor). R_f = 0.71 (**13j**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: m.p. 138 – 142 °C (MTBE/*n*-pentane); $[\alpha]_D^{25}$ = -55.7 (c = 0.70, CHCl₃), $[\alpha]_{365}^{25}$ = -209.1 (c = 0.70, CHCl₃); IR (ATR): 3066, 3025, 2953, 2921, 2321, 2086, 1688, 1591, 1515, 1481, 1454, 1399, 1351, 1266, 1207, 1158, 1120, 1069, 1013, 920, 890, 835, 812, 756, 735, 691 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.65 (ddd, J = 14.4 Hz, 11.9 Hz, 5.5 Hz, 1H), 2.01 (d, J = 14.4 Hz, 1H), 2.69 (dd, 13.4 Hz, 11.4 Hz, 1H), 3.14 – 3.21 (m, 2H), 3.25 (dd, J = 13.9 Hz, 3.5 Hz, 1H), 3.57 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 4.98 – 5.04 (m, 1H), 7.21 – 7.38 (m, 8H), 7.61 (d, J = 8.9 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 30.0, 30.7, 42.0, 43.3, 73.5, 100.5, 121.2, 121.8 (q, J =


(11) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.

269.6 Hz, CF₃), 126.5, 127.0, 128.6, 128.9, 129.0, 129.4, 129.7, 132.1, 135.3, 137.7, 138.8 (q, *J* = 38.2 Hz), 139.2, 150.2, 195.3 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.4 ppm; MS (CI, 100 eV): *m/z* 557 (100), 555 (M+H⁺, 95%), 537 (33), 536 (13), 535 (36), 465 (19), 463 (19), 265 (46), 62 (20); elemental analysis calcd (%) for C₂₈H₂₂BrF₃N₂O₂: C 60.55, H 3.99, N 5.04; found: C 60.35, H 4.03, N 4.73.



2-((4*R*,6*S*)-1,4-Dimethyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)-1-phenylethanone (13k) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13k** as a colorless oil. For analytical purposes a sample of the *trans*-diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7μm 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), *t_R* = 15.17 min (*trans*), *t_R* ~ 15.90 min (*cis*).¹² The *ee* (*trans* 91%, *cis* 95%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 0.7 mL/min), *t_R* = 12.33 min (*trans*, major), 15.92 min (*trans*, minor), *t_R* = 17.46 min (*cis*, major), 19.16 min (*cis*, minor). *R_f* = 0.28 (**13k**), (*n*-pentane/Et₂O 2:1);

trans-Diastereomer: [α]_D²⁵ = +26.4 (*c* = 1.17, CHCl₃), IR (ATR): 2960, 2327, 2095, 1686, 1585, 1546, 1498, 1430, 1395, 1355, 1261, 1162, 1116, 1032, 963, 899, 854, 746, 690, 649, 567 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.31 (d, *J* = 6.9 Hz, 3H), 1.86 (dt, *J* = 13.9 Hz, 2.5 Hz, 1H), 1.91 (ddd, *J* = 14.4 Hz, 10.4 Hz, 5.5 Hz, 1H), 3.01 – 3.07 (m, 1H), 3.21 (dd, *J* = 16.8 Hz, 6.0 Hz, 1H), 3.58 (s, 3H), 3.62 (dd, *J* = 16.8 Hz, 6.4 Hz, 1H), 4.94 – 4.99 (m, 1H), 7.51 (t, *J* = 7.4 Hz, 2H), 7.62 (tt, *J* = 6.9 Hz, 1.5 Hz, 1H), 8.00 (dd, *J* = 8.4 Hz, 1.0 Hz, 2H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 22.3, 23.0, 33.8, 35.2, 43.2, 72.8, 100.4, 121.6 (q, *J* = 269.6 Hz, CF₃), 128.2, 128.8, 133.6, 136.7, 137.0 (q, *J* = 38.2 Hz), 150.1, 196.5 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.9 ppm; MS (CI, 100 eV): *m/z* 339 (M+H⁺, 100%), 338 (14), 320 (11), 319 (45); elemental analysis calcd (%) for C₁₇H₁₇F₃N₂O₃: C 60.35, H 5.06, N 8.28; found: C 60.29, H 5.28, N 8.61.




1-(4-Bromophenyl)-2-((4*R*,6*S*)-1,4-dimethyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-*c*]pyrazol-6-yl)ethanone (13l) was purified by flash chromatography (*n*-pentane/Et₂O 1:1) yielding an inseparable mixture of diastereomers of **13l** as a colorless oil. For analytical purposes a sample of the *trans*-

(12) The *cis*-diastereomer was only observed as a shoulder of the major peak and could not be completely separated.

diastereomer was obtained via preparative HPLC (LiChrosorb Si 60 7 μ m 250x25 mm, *n*-pentane/diethylether 6:4, 18 mL/min), t_R = 15.10 min (*trans*), t_R ~ 15.90 min (*cis*).¹² The *ee* (*trans* 87%, *cis* 87%) was determined by HPLC on a chiral stationary phase (Daicel AD, *n*-heptane/*i*PrOH 95:5, 0.7 mL/min), t_R = 15.41 min (*trans*, major), 18.41 min (*trans*, minor), t_R = 20.20 min (*cis*, major), 23.58 min (*cis*, minor). R_f = 0.29 (**13l**), (*n*-pentane/Et₂O 2:1);


trans-Diastereomer: $[\alpha]_D^{24}$ = +14.4 (c = 0.95, CHCl₃), $[\alpha]_{365}^{24}$ = +70.8 (c = 0.95, CHCl₃); IR (ATR): 3457, 3074, 2922, 2575, 2423, 2289, 1919, 1691, 1579, 1383, 1252, 1021, 913, 808, 727, 662, 602 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 1.30 (d, J = 6.9 Hz, 3H), 1.84 (dt, J = 13.9 Hz, 2.5 Hz, 1H), 1.90 (ddd, J = 13.9 Hz, 10.4 Hz, 5.5 Hz, 1H), 3.01 – 3.07 (m, 1H), 3.17 (dd, J = 16.8 Hz, 6.0 Hz, 1H), 3.56 (dd, J = 16.8 Hz, 6.4 Hz, 1H), 3.57 (s, 3H), 4.92 – 4.97 (m, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.86 (d, J = 8.4 Hz, 2H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 22.3, 23.0, 33.8, 35.2, 43.2, 72.6, 100.4, 121.6 (q, J = 268.3 Hz, CF₃), 128.9, 129.6, 132.1, 135.4, 137.0 (q, J = 38.2 Hz), 150.0, 195.4 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.9 ppm; MS (CI, 100 eV): m/z 420 (100), 419 (48), 418 (M+H⁺, 87%), 417 (18), 401 (14), 400 (84), 399 (15), 398 (81), 339 (16), 320 (11), 217 (23), 203 (10), 185 (46), 183 (47); HRMS (ESI): m/z calcd for C₁₇H₁₇BrF₃O₂N₂⁺: 417.0420 [M+H⁺]; found: 417.0421.



(*R,E*)-Ethyl 5-(5-hydroxy-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)hex-2-enoate (13m') was purified by flash chromatography (*n*-pentane/Et₂O 1:2 – 1:5) yielding an inseparable mixture of *E/Z*-isomers of **13m'** (*E/Z* 18:1) as a colorless oil.

R_f = 0.23 (**13m'**), (*n*-pentane/Et₂O 1:5); $[\alpha]_D^{25}$ = -10.1 (c = 1.0, CHCl₃), $[\alpha]_{365}^{25}$ = +109.8 (c = 1.0, CHCl₃); IR (ATR): 2968, 2089, 1698, 1567, 1483, 1376, 1271, 1162, 1121, 1040, 981, 857, 725 cm⁻¹; *E*-Isomer: ¹H NMR (600 MHz, CDCl₃): δ = 1.23 (d, J = 7.4 Hz, 3H), 1.28 (t, J = 7.2 Hz, 3H), 2.40 - 2.47 (m, 1H), 2.51 - 2.57 (m, 1H), 2.92 – 3.00 (m, 1H), 3.64 (s, 3H), 4.16 (q, J = 7.1 Hz, 2H), 5.74 (d, J = 15.9 Hz, 1H), 6.77 (dt, J = 15.4, 7.4 Hz, 1H) ppm;¹³ ¹³C NMR (151 MHz, CDCl₃): δ = 16.0, 20.1, 28.2, 34.0, 38.6, 60.8, 106.4, 121.5 (q, J = 268.3 Hz, CF₃), 122.3, 137.2 (q, J = 36.9 Hz), 148.2, 149.8, 167.6 ppm; ¹⁹F NMR (564 MHz, CDCl₃): δ = 61.9 ppm; MS (CI, 100 eV): m/z 307 (M+H⁺, 64%), 237 (100), 221 (44), 193 (16), 167 (21); HRMS (ESI): m/z calcd for C₁₃H₁₈F₃N₂O₃⁺: 307.1264 [M+H⁺]; found: 307.1264.

(13) The signal for OH was not observed.



(4R)-1,4-Dimethyl-3-(trifluoromethyl)-1,4,5,6-tetrahydropyrano[2,3-c]pyrazol-6-ol (9a) was purified by flash chromatography (*n*-pentane/Et₂O 1:5) yielding an inseparable mixture of **9a** and **9a'** as an off-white solid.

$R_f = 0.25$ (**9a**), (*n*-pentane/Et₂O 1:5); m.p. 82-86 °C (Et₂O/*n*-pentane); $[\alpha]_D^{26} = +17.1$ ($c = 1.0$, CHCl₃), $[\alpha]_{365}^{26} = +50.6$ ($c = 1.0$, CHCl₃); IR (ATR): 3197, 2954, 2884, 1579, 1553, 1498, 1431, 1400, 1338, 1258, 1167, 1117, 1048, 1017, 984, 948, 872, 841, 745, 718, 700 cm⁻¹; *trans*-Diastereomer:¹⁴ ¹H NMR (300 MHz, CDCl₃): $\delta = 1.29$ (d, $J = 6.9$ Hz, 3H), 1.72 (ddd, $J = 13.9, 7.5, 1.9$ Hz, 1H), 2.06 (dt, $J = 13.9, 5.6$ Hz, 1H), 3.05-3.15 (m, 1H), 3.63 (s, 3H), 5.37 (br s, OH), 5.72 (dd, $J = 5.3, 1.9$ Hz, 1H) ppm; ¹³C NMR (75 MHz, CDCl₃): $\delta = 20.8, 21.4, 33.6, 36.5, 95.5, 100.3, 121.5$ (q, $J = 269.3$ Hz, CF₃), 136.8 (q, $J = 38.3$ Hz), 148.9 ppm; ¹⁹F NMR (282 MHz, CDCl₃): $\delta = 61.7$ ppm; MS (CI, 100 eV): m/z 237 (M+H⁺, 100%), 217 (52), 193 (12); elemental analysis calcd (%) for C₉H₁₁F₃N₂O₂: C 45.77, H 4.69, N 11.86; found: C 45.78, H 4.43, N 11.87.

(14) The signals were assigned via 2D NMR techniques (COSY, HMQC, HMBC).

8. NMR Spectra




Figure S1. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13a.




Figure S2. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-13a.




Figure S3. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-**13b**.




Figure S4. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-**13b**.




Figure S5. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-**13c**.




Figure S6. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-**13c**.




Figure S7. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13d.




Figure S8. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-13d.




Figure S9. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13e.




Figure S10. ¹³C NMR spectrum (75 MHz, CDCl₃) of *trans*-13e.




Figure S11. ¹H NMR spectrum (600 MHz, CDCl₃) of *cis*-13e.




Figure S12. ¹³C NMR spectrum (75 MHz, CDCl₃) of *cis*-13e.




Figure S13. ^1H NMR spectrum (600 MHz, CDCl_3) of *trans*-**13f**.




Figure S14. ^{13}C NMR spectrum (151 MHz, CDCl_3) of *trans*-**13f**.




Figure S15. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13g.




Figure S16. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-13g.




Figure S17. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13h.




Figure S18. ¹³C NMR spectrum (100 MHz, CDCl₃) of *trans*-13h.




Figure S19. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13i.




Figure S20. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-13i.




Figure S21. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-**13j**.




Figure S22. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-**13j**.




Figure S23. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-**13k**.




Figure S24. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-**13k**.




Figure S25. ¹H NMR spectrum (600 MHz, CDCl₃) of *trans*-13l.




Figure S26. ¹³C NMR spectrum (151 MHz, CDCl₃) of *trans*-13l.




Figure S27. ^1H NMR spectrum (600 MHz, CDCl_3) of **13m'**; mixture of E/Z isomers.






Figure S28. ^{13}C NMR spectrum (151 MHz, CDCl_3) of **13m'**; mixture of E/Z isomers.



9. NOESY of Compounds **13e** and **13f**





Figure S31. NOESY spectrum (600 MHz, CDCl₃) of **trans-13e**.





Figure S32. NOESY spectrum (600 MHz, CDCl₃) of **cis-13e**.




Figure S33. NOESY spectrum (600 MHz, CDCl₃) of *trans*-13f.

10. HPLC Chromatograms







Figure S34. HPLC chromatogram of **13a**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	3.09	0.14	3.37	37.05	0.39
2	6.36	0.15	634.33	6248.35	66.28
3	7.08	0.18	17.34	203.76	2.16
4	8.16	0.19	34.13	438.87	4.66
5	9.65	0.24	161.49	2498.67	26.51
Total				9426.70	100.00

Figure S35. HPLC chromatogram of **13b**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.






Figure S36. HPLC chromatogram of **13c**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.41	0.16	3.99	40.77	0.71
2	4.82	0.16	4.08	42.87	0.74
3	12.88	0.40	164.72	4348.09	75.49
4	16.42	0.50	3.70	123.70	2.15
5	18.02	0.57	30.84	1161.59	20.17
6	29.92	1.05	0.67	42.58	0.74
Total				5759.59	100.00

Figure S37. HPLC chromatogram of **13d**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.










Figure S38. HPLC chromatogram of *trans*-13e; comparison of racemic (top) and non-racemic (bottom).



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	10.26	0.34	43.98	985.36	97.68
2	14.27	0.38	0.82	23.36	2.32
Total				1008.73	100.00

Figure S39. HPLC chromatogram of **cis-13e**; comparison of racemic (top) and non-racemic (bottom).



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	3.23	0.19	2.20	30.93	0.88
2	3.79	0.13	0.87	6.56	0.19
3	4.16	0.16	0.40	4.31	0.12
4	13.37	0.47	64.64	1985.61	56.23
5	17.49	0.58	6.60	267.91	7.59
6	25.54	0.89	20.64	1235.96	35.00
Total				3531.27	100.00

The signal at 25 min belongs to the unseparated mixture of enantiomers of the second diastereomer.

Figure S40. HPLC chromatogram of **13f**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.




Figure S41. HPLC chromatogram of **13g**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.







Figure S42. HPLC chromatogram of **13h**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.38	0.19	15.02	212.92	2.74
2	9.77	0.22	1.17	20.49	0.26
3	10.69	0.52	10.43	327.77	4.23
4	13.32	0.65	158.23	7196.56	92.77
Total				7757.74	100.00

Figure S43. HPLC chromatogram of *trans*-13i; comparison of racemic (top) and non-racemic (bottom).




Figure S44. HPLC chromatogram of **trans-13j**; comparison of racemic (top) and non-racemic (bottom).




Figure S45. HPLC chromatogram of **13k**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.




Figure S46. HPLC chromatogram of **13I**; comparison of racemic (top) and non-racemic (bottom); mixture of diastereomers.